Renaissance Capital logo

IRWD News

Ironwood Pharma quiet period ends March 14

Ironwood Pharmaceuticals, which is developing a new treatment for irritable bowel syndrome and constipation, will see its quiet period end on Sunday, Mar. 14. On Feb. 2, the company raised $188 million by offering 16.7 million shares at $11.25, below the range ...read more

One out of four IPOs prices this week, others postpone

PMG

In a continuation of what was a rocky start to the 2010 IPO market last month, three of the four deals that were scheduled to price this week were postponed. Workers' compensation risk insurer Patriot Risk Management (PMG) pushed its IPO out to next week...read more

Ironwood Pharmaceuticals prices IPO at $11.25, below the range

Ironwood Pharmaceuticals, which is developing a new treatment for irritable bowel syndrome and constipation, raised $188 million by offering 16,666,670 shares at $11.25, well below its anticipated range of $14 to $16. Ironwood is the first biotech IPO of 2010. ...read more

5 IPOs planned for the week of Feb 1

The following IPOs are expected to price this week: Film Department Holdings (TFDI), a recently formed independent movie production company, plans to raise $85 million by offering 6.5 million shares at a price range of $12-$14. At the mid-point of the...read more